MarketCap
Facebook
X
Telegram
ADMA Biologics Balance Sheet 2025-2010 | ADMA
Brief balance sheet overview of ADMA Biologics
The review uses the five latest available annual reports between 2021 and 2025.
The asset base grew from $276.3 million to $624.2 million, or +126%. Average annual growth of roughly 22.6% was strong.
Liabilities increased less than assets, posting +8.8% versus +126%. That relationship usually strengthens the balance sheet.
The equity ratio reached 76.5% from 51.1%. A high capital share reduces dependence on liabilities.
The period ended with net cash: net debt stood at -$17.2 million. This supports financial flexibility.
Cash represents 14% of assets versus 18.5% initially, showing how the immediate liquidity reserve changed.
The balance sheet carries negative retained earnings of -$161.7 million. The figure may result from accumulated losses or an active capital return policy.
Conclusion
ADMA Biologics's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet ADMA Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-17.2 M | -29.6 M | -40.5 M | -74.9 M | -43 M | 37.4 M | 58 M | 21.5 M | -137 K | 10.3 M | 5.29 M | -16.8 M | -21.1 M | -8.57 M | 9.81 M | - |
Long Term Debt |
69.3 M | 72.3 M | 9.78 M | 10.7 M | 7.46 M | 93 M | 83.2 M | 44.1 M | 43 M | 14.1 M | 15.7 M | 9.67 M | 5 M | 3.88 M | - | - |
Long Term Debt Current |
1.1 M | 1.22 M | 1.04 M | 905 K | 591 K | 366 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 99.5 M | 86.9 M | 59.5 M | 58.2 M | 16.9 M | 18.7 M | 11.4 M | 6.75 M | 4.31 M | - | - |
Total Current Liabilities |
69.5 M | 55.5 M | 49.8 M | 39.3 M | 30.4 M | 19.9 M | 14 M | 9.63 M | 9.44 M | 11.2 M | 4.22 M | 4.2 M | 3.66 M | 1.82 M | - | - |
Total Liabilities |
147 M | 140 M | 194 M | 196 M | 135 M | 119 M | 101 M | 69.1 M | 67.7 M | 28.1 M | 22.9 M | 16 M | 10.4 M | 6.13 M | 9.82 K | - |
Deferred Revenue |
- | 143 K | 182 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 145 K | 145 K | - | 75.6 K | - | - | - |
Retained Earnings |
-162 M | -309 M | -506 M | -478 M | -412 M | -340 M | -265 M | -216 M | -151 M | -107 M | -87.4 M | -58.5 M | -52.6 M | -37.1 M | -140 K | - |
Total Assets |
624 M | 489 M | 329 M | 348 M | 276 M | 208 M | 127 M | 88.9 M | 108 M | 23.7 M | 23.7 M | 32 M | 32 M | 15.6 M | 8.51 K | - |
Cash and Cash Equivalents |
87.6 M | 103 M | 51.4 M | 86.5 M | 51.1 M | 55.9 M | 26.8 M | 22.8 M | 43.1 M | 9.91 M | 10.4 M | 17.2 M | 26.1 M | 12.5 M | 87.8 K | 229 K |
Book Value |
477 M | 349 M | 135 M | 152 M | 141 M | 88.2 M | 26.2 M | 19.8 M | 40.3 M | -4.46 M | 821 K | 15.9 M | 21.6 M | 9.42 M | -1.31 K | - |
Total Shareholders Equity |
477 M | 349 M | 135 M | 152 M | 141 M | 88.2 M | 26.2 M | 19.8 M | 40.3 M | -4.46 M | 821 K | 6.01 M | 21.6 M | 9.42 M | - | -3.93 M |
All numbers in USD currency
Quarterly Balance Sheet ADMA Biologics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
194 M | 70.1 M | 9.3 M | 8.3 M | 72.3 M | 8.86 M | 9.18 M | 9.49 M | 9.78 M | 9.97 M | 10.2 M | 10.5 M | 10.7 M | 10.6 M | 10.9 M | 7.28 M | 7.46 M | 6.92 M | 7.07 M | - | 4.33 M | 4.33 M | 4.33 M | - | - | - | - | - | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 1.79 M | 1.79 M | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
275 M | 138 M | 160 M | 137 M | 140 M | 159 M | 188 M | 197 M | 194 M | 198 M | 196 M | 195 M | 196 M | 200 M | 183 M | 181 M | 135 M | 136 M | 121 M | 123 M | 119 M | 119 M | 119 M | 119 M | 101 M | 101 M | 101 M | 101 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 67.7 M | 67.7 M | 67.7 M | 67.7 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 21 M | 21 M | 21 M | 21.2 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | 2.54 M | 2.54 M | 2.54 M | 2.54 M |
Deferred Revenue |
- | - | 143 K | 143 K | 143 K | 143 K | 1.13 M | 1.12 M | 182 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | - | 143 K | 143 K | 143 K | - | 143 K | - | - | - | 143 K | - | - | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-116 M | -211 M | -247 M | -282 M | -309 M | -420 M | -456 M | -488 M | -506 M | -489 M | -491 M | -485 M | -478 M | -466 M | -451 M | -437 M | -412 M | -395 M | -378 M | -359 M | -340 M | -340 M | -340 M | -340 M | -265 M | -265 M | -265 M | -265 M | -216 M | -216 M | -216 M | -216 M | -151 M | -151 M | -151 M | -151 M | -107 M | -107 M | -107 M | -107 M | -87.4 M | -87.4 M | -87.4 M | -87.4 M | -69.4 M | -69.4 M | -69.4 M | -69.4 M | -52.6 M | -52.6 M | -52.6 M | -52.6 M | -37.1 M | -37.1 M | -37.1 M | -37.1 M | -29.8 M | -29.8 M | -29.8 M | -29.8 M |
Total Assets |
665 M | 569 M | 558 M | 511 M | 489 M | 391 M | 376 M | 351 M | 329 M | 349 M | 343 M | 341 M | 348 M | 301 M | 297 M | 308 M | 276 M | 239 M | 233 M | 236 M | 208 M | 208 M | 208 M | 208 M | 127 M | 127 M | 143 M | 127 M | 88.9 M | 88.9 M | 88.9 M | 88.9 M | 108 M | 108 M | 108 M | 108 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 27 M | 27 M | 27 M | 27.2 M | 32 M | 32 M | 32 M | 32 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 2.93 M | 2.93 M | 2.93 M | 2.93 M |
Cash and Cash Equivalents |
138 M | 61.4 M | 90.3 M | 71.6 M | 103 M | 86.7 M | 88.2 M | 45.3 M | 51.4 M | 74.2 M | 62.5 M | 69.2 M | 86.5 M | 34.9 M | 52.4 M | 69.5 M | 51.1 M | 34.4 M | 42.4 M | 62 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 22.8 M | 22.8 M | 22.8 M | 43.1 M | 43.1 M | 43.1 M | 43.1 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 87.8 K | 87.8 K | 87.8 K | 87.8 K |
Book Value |
390 M | 431 M | 398 M | 373 M | 349 M | 232 M | 188 M | 154 M | 135 M | 151 M | 147 M | 146 M | 152 M | 100 M | 114 M | 127 M | 141 M | 103 M | 112 M | 113 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 26.2 M | 26.2 M | 42.4 M | 26.2 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | -4.46 M | -4.46 M | -4.46 M | -4.46 M | 821 K | 821 K | 821 K | 821 K | 6.01 M | 6.01 M | 6.01 M | 6.01 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 386 K | 386 K | 386 K | 386 K |
Total Shareholders Equity |
390 M | 431 M | 398 M | 373 M | 349 M | 232 M | 188 M | 154 M | 135 M | 151 M | 147 M | 146 M | 152 M | 100 M | 114 M | 127 M | 141 M | 103 M | 112 M | 113 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | -4.46 M | -4.46 M | -4.46 M | -4.46 M | 821 K | 821 K | 821 K | 821 K | 6.01 M | 6.01 M | 6.01 M | 6.01 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 386 K | 386 K | 386 K | 386 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of ADMA Biologics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
